Boothbay Fund Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.68M | Buy |
+148,927
| New | +$1.68M | 0.03% | 401 |
|
|
2023
Q4 | – | Sell |
-30,790
| Closed | -$297K | – | 1639 |
|
|
2023
Q3 | $297K | Buy |
30,790
+2,692
| +10% | +$25.9K | 0.01% | 1073 |
|
|
2023
Q2 | $253K | Hold |
28,098
| – | – | 0.01% | 1184 |
|
|
2023
Q1 | $221K | Buy |
+28,098
| New | +$221K | ﹤0.01% | 1453 |
|
|
2021
Q4 | – | Sell |
-14,036
| Closed | -$245K | – | 1856 |
|
|
2021
Q3 | $245K | Sell |
14,036
-2,820
| -17% | -$49.2K | 0.01% | 1221 |
|
|
2021
Q2 | $404K | Sell |
16,856
-16,019
| -49% | -$384K | 0.01% | 972 |
|
|
2021
Q1 | $845K | Sell |
32,875
-80,658
| -71% | -$2.07M | 0.03% | 553 |
|
|
2020
Q4 | $2.16M | Sell |
113,533
-18,289
| -14% | -$347K | 0.08% | 204 |
|
|
2020
Q3 | $1.66M | Buy |
131,822
+6,920
| +6% | +$87.1K | 0.1% | 229 |
|
|
2020
Q2 | $1.51M | Buy |
124,902
+16,410
| +15% | +$199K | 0.1% | 217 |
|
|
2020
Q1 | $830K | Buy |
108,492
+64,743
| +148% | +$495K | 0.07% | 294 |
|
|
2019
Q4 | $779K | Buy |
43,749
+13,924
| +47% | +$248K | 0.07% | 320 |
|
|
2019
Q3 | $346K | Buy |
+29,825
| New | +$346K | 0.03% | 457 |
|
|
2017
Q4 | – | Sell |
-21,665
| Closed | -$146K | – | 678 |
|
|
2017
Q3 | $146K | Hold |
21,665
| – | – | 0.02% | 452 |
|
|
2017
Q2 | $159K | Hold |
21,665
| – | – | 0.03% | 501 |
|
|
2017
Q1 | $169K | Buy |
21,665
+5,319
| +33% | +$41.5K | 0.03% | 541 |
|
|
2016
Q4 | $116 | Buy |
+16,346
| New | +$116 | 0.03% | 605 |
|